SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales slipped to Rs. 2169.67 millions, down -30.22% for the September 2021 quarter as against Rs. 3109.32 millions during the year-ago period.The Net Loss for the quarter ended September 2021 is Rs. -214.33 millions as compared to Net Profit of Rs. 303.39 millions of corresponding quarter ended September 2020Operating profit Margin for the quarter ended September 2021 slipped to -51.12% as compared to 542.50% of corresponding quarter ended September 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 2169.67 3109.32 -30.22 4177.70 5517.03 -24.28 11239.73 9044.41 24.27
Other Income 53.41 104.11 -48.70 178.81 291.41 -38.64 473.71 991.70 -52.23
PBIDT -51.12 542.50 -109.42 -212.69 651.73 -132.63 1428.38 85.59 1568.86
Interest 10.29 1.64 527.44 11.49 3.22 256.83 13.01 12.82 1.48
PBDT -61.41 540.86 -111.35 -224.18 648.51 -134.57 1415.37 72.77 1844.99
Depreciation 204.49 189.27 8.04 405.56 372.39 8.91 758.92 710.90 6.75
PBT -265.90 351.59 -175.63 -629.74 276.12 -328.07 656.45 -638.13 -202.87
TAX -51.57 48.20 -206.99 -137.11 48.20 -384.46 115.63 -74.96 -254.26
Deferred Tax -51.57 0.00 0.00 -139.48 0.00 0.00 109.43 -74.96 -245.98
PAT -214.33 303.39 -170.65 -492.63 227.92 -316.14 540.82 -563.17 -196.03
Equity 140.81 140.81 0.00 140.81 140.81 0.00 140.81 140.81 0.00
PBIDTM(%) -2.36 17.45 -113.50 -5.09 11.81 -143.10 12.71 0.95 1242.95

Unichem Lab Share Price

350.85 4.85 (1.40%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×